Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Home workouts may boost prostate cancer Patients' Well-Being

NCT ID NCT07126860

Symptom relief Sponsor: Ludwig-Maximilians - University of Munich Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a structured home-based exercise program combining strength and aerobic training can improve quality of life, fitness, and immune function in 150 men with prostate cancer. Participants are randomly assigned to either the exercise program or usual care. The program uses resistance bands and bodyweight exercises, with training 3-6 days per week for at least 12 weeks. The goal is to see if exercise can reduce side effects like fatigue, muscle loss, and depression.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
structured combined resistance and aerobic training
What this could lead to
If it works, this could provide a simple, home-based exercise program to improve quality of life and physical fitness for men with prostate cancer.
What could go wrong
This is a relatively small, early-stage study (150 participants) testing a behavioral intervention, so results may not be generalizable. Participants must be motivated to exercise 3-6 days per week, and adherence may vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2024

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Participant must have a histologically diagnosed adenocarcinoma of the prostate 2. Participant has to be ≥ 18 years of age 3. Participant must have either localized, locally advanced, or metastatic PC which has been treated or is planned to be treated either by RP, EBRT, androgen deprivation therapy (ADT), androgen receptor signaling inhibitor (ARSI), or any combination 4. Participant must understand and remember the training regimen 5. Participant must have a smartphone to connect a wearable device 6. Participant must have a smartphone or computer to access the online platform 7. Participant has to be able to speak, understand, and read German or English 8. Participant must sign an informed consent form (ICF) Exclusion Criteria: 1. Cardiovascular/neurological/musculoskeletal comorbidities with contraindications for resistance or aerobic training 2. High risk of pathological fracture due to unstable bone metastases (note: patients with bone metastasis are generally eligible for participation in the study and program as long as there is no acute high risk of fracture) 3. Any condition for which it may not be in the best interest of the patient to participate in the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metastatic prostate cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

metastatic prostate carcinoma Motor Activity prostate cancer Psychological Well-Being

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Metastatic prostate cancer Prostate cancer Prostate cancer (post prostatectomy) Prostate cancer non-metastatic Prostate cancer patients treated by radiotherapy

Contacts and locations

Locations

  • Ludwig Maximilian University Hospital Campus Großhadern

    Munich, Bavaria, 81377, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.